PriceTargets.com logo

Dogwood Therapeutics - DWTX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $12.00
  • Forecasted Upside: 330.11%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.79 As of 01/30/2026 05:00 PM ET
▼ -0.11 (-3.79%)

This chart shows the closing price for DWTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Dogwood Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DWTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DWTX

Analyst Price Target is $12.00
▲ +330.11% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Dogwood Therapeutics in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 330.11% upside from the last price of $2.79.

This chart shows the closing price for DWTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Dogwood Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/3/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/2/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/1/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/30/2026HC WainwrightReiterated RatingBuy ➝ Buy$12.00
12/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/15/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/30/2025HC WainwrightBoost TargetBuy ➝ Buy$10.00 ➝ $12.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
4/23/2025HC WainwrightUpgradeNeutral ➝ Buy$10.00
(Data available from 2/1/2021 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2025
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/4/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
11/3/2025
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/2/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/1/2026

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Dogwood Therapeutics logo
Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.
Read More

Today's Range

Now: $2.79
Low: $2.75
High: $3.04

50 Day Range

MA: $4.60
Low: $2.67
High: $6.82

52 Week Range

Now: $2.79
Low: $2.60
High: $15.00

Volume

52,972 shs

Average Volume

61,203 shs

Market Capitalization

$6.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.9

Frequently Asked Questions

What sell-side analysts currently cover shares of Dogwood Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Dogwood Therapeutics in the last year: HC Wainwright, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for DWTX.

What is the current price target for Dogwood Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Dogwood Therapeutics in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 330.1%. HC Wainwright has the highest price target set, predicting DWTX will reach $12.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $12.00 for Dogwood Therapeutics in the next year.
View the latest price targets for DWTX.

What is the current consensus analyst rating for Dogwood Therapeutics?

Dogwood Therapeutics currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DWTX, but not buy more shares or sell existing shares.
View the latest ratings for DWTX.

What other companies compete with Dogwood Therapeutics?

Other companies that are similar to Dogwood Therapeutics include Rallybio, Aytu BioPharma, Senti Biosciences, Dare Bioscience and Lixte Biotechnology. Learn More about companies similar to Dogwood Therapeutics.

How do I contact Dogwood Therapeutics' investor relations team?

Dogwood Therapeutics' physical mailing address is 44 Milton Avenue, Alpharetta, GA 30009, United States. The company's listed phone number is (866) 620-8655 and its investor relations email address is [email protected]. The official website for Dogwood Therapeutics is www.dwtx.com. Learn More about contacing Dogwood Therapeutics investor relations.